CIK 0001676725 · Large accelerated filer
IDEAYA Biosciences, Inc.
Sign in to watch- Ticker
- IDYA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 474268251
- Phone
- 650-443-6209
- Business address
- 5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $985,397
- in 1 filing, $985K under 10b5-1 plans
Net −$985,397. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 67 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-06 | Hata Yujiro S President and CEO | Option exercise 10b5-1 | +26,338 | $4.31 | $114K | 717,033 |
| 2026-10-06 | Hata Yujiro S President and CEO | Sale 10b5-1 | −25,538 | $37.39 | $955K | 691,495 |
| 2026-10-06 | Hata Yujiro S President and CEO | Sale 10b5-1 | −800 | $38.26 | $31K | 690,695 |
| 2026-10-06 | Hata Yujiro S President and CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −26,338 | 23,116 | ||
| 2026-07-07 | Ruiz Briseno Andres Chief Accounting Officer | Option exercise 10b5-1 | +9,550 | $12.86 | $123K | 36,016 |
| 2026-07-07 | Ruiz Briseno Andres Chief Accounting Officer | Sale 10b5-1 | −9,550 | $40.01 | $382K | 26,466 |
| 2026-07-07 | Ruiz Briseno Andres Chief Accounting Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −9,550 | 19,200 | ||
| 2026-06-16 | YARNO WENDY L Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2026-06-16 | Stein Jeffrey Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2026-06-16 | ROSEN TERRY J Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2026-06-16 | Morrison Scott W Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2026-06-16 | MACKEY CATHERINE J Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2026-06-16 | Hampton Malcolm Garret Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2026-03-02 | Stein Jeffrey Director | Purchase | +50,000 | $32.96 | $1.6M | 54,281 |
| 2026-01-30 | Bleharski Joshua Chief Financial Officer | Grant or award · Stock Option (right to buy) | +170,000 | 170,000 | ||
| 2026-01-30 | WHITE MICHAEL ANTHONY Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +190,000 | 190,000 | ||
| 2026-01-30 | Beaupre Darrin Chief Medical Officer | Grant or award · Stock Option (right to buy) | +175,000 | 175,000 | ||
| 2026-01-30 | DORMAN STUART Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +155,000 | 155,000 | ||
| 2026-01-30 | Hata Yujiro S President and CEO | Grant or award · Stock Option (right to buy) | +600,000 | 600,000 | ||
| 2026-01-30 | Snyder Douglas B. SVP, General Counsel | Grant or award · Stock Option (right to buy) | +130,000 | 130,000 |
Page 1 of 10 · 186 trades